Intracerebral microinjection of stannous 2-ethylhexanoate affects dopamine turnover in cerebral cortex and locomotor activity in rats

Journal of Biomedical Materials Research - Part B Applied Biomaterials

Volumn 87, Issue 2, 2008, Pages 381-386

  Yamada, Takashi ^a   Jung, Duk Young ^a   Sawada, Rumi ^a   Tsuchiya, Toshie ^a  

^a NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

Author keywords

Dopamine, serotonin, cytotoxicity; Open field test; Stannous 2 ethylhexanoate

Indexed keywords

ABS RESINS; ACIDS; BRAIN; LACTIC ACID; ORGANIC ACIDS; ORGANIC POLYMERS; POLYMERS; RAT CONTROL;

CELL VIABILITIES; CENTRAL NERVOUS SYSTEMS; CEREBRAL CORTICES; CO-POLYMERS; CONTROL GROUPS; CYTOTOXIC; DOPAMINE, SEROTONIN, CYTOTOXICITY; IN VITRO; L-LACTIC ACIDS; LATERAL VENTRICLES; LOCOMOTOR ACTIVITIES; MICROINJECTION; MITOCHONDRIAL ACTIVITIES; NEUROTOXICITY; OPEN FIELD TEST; RAT BRAINS; STANNOUS 2-ETHYLHEXANOATE;

TIN;

2 ETHYLHEXANOIC ACID; DOPAMINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; ASTROCYTE; BRAIN; BRAIN CORTEX; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DOPAMINERGIC NERVE CELL; IN VITRO STUDY; LATERAL BRAIN VENTRICLE; LOCOMOTION; LONG TERM EXPOSURE; MALE; MICROINJECTION; MITOCHONDRION; MOBILIZATION; NEUROTRANSMISSION; NONHUMAN; RAT;

ANIMALS; ASTROCYTES; BODY WEIGHT; CEREBRAL CORTEX; DOPAMINE; HEXANOIC ACIDS; MALE; MICROINJECTIONS; MOTOR ACTIVITY; RATS; RATS, WISTAR; TETRAZOLIUM SALTS;

EID: 55049100270     PISSN: 15524973     EISSN: 15524981     Source Type: Journal    
DOI: 10.1002/jbm.b.31115     Document Type: Article

References (28)

1. Tsuji H, Nishikawa M, Sakamoto Y, Itsuno S. Novel preparation method for poly(L-lactide)-based block copolymers: Extended chain crystallites as a solid-state macro-coinitiator. Biomacromolecules 2007;8:1730-1738.
2. L-lactide) on the response of osteoblast-like MC3T3-E1 cells. Biomaterials 2000;12:1259-1267.
3. Ahmed S, Tsuchiya T. A mouse strain difference in tumorigenesis induced by biodegradable polymers. J Biomed Mater Res A 2006;79:409-417.
4. Penninks AH, Hilgers L, Seinen W. The absorption, tissue distribution and excretion of di-n-octyltin dicholoride in rats. Toxicology 1987;44:107-120.
5. Moody DE, Reddy JK. Serum triglyceride and cholesterol contents in male rats receiving diets containing plasticizers and analogues of the ester 2-ethylhexanol. Toxicol Lett 1982;10:379-383.
6. Albro PW. The metabolism of 2-ethylhexanol in rats. Xenobiotica 1975;5:625-636.
7. Badr MZ, Handler JA, Whittaker M, Kauffman FC, Thurman RG. Interactions between plasticizers and fatty acid metabolism in the perfused rat liver and in vitro. Inhibition of ketogenesis by 2-ethylhexanol. Biochem Pharmacol 1990;39:715-721.
8. Noel L, Leblanc JC, Guerin T. Determination of several elements in duplicate meals from catering establishments using closed vessel microwave digestion with inductively coupled plasma mass spectrometry detection: Estimation of daily dietary intake. Food Addit Contam 2003;20:44-56.
9. Ysart G, Miller P, Croasdale M, Crews H, Robb P, Baxter M, de L'Argy C, Harrison N. 1997 UK Total Diet Study - Dietary exposures to aluminium, arsenic, cadmium, chromium, copper, lead, mercury, nickel, selenium, tin and zinc. Food Addit Contam 2000;17:775-786.
10. Jonker D, Woutersen RA, van Bladeren PJ, Til HP, Feron VJ. Four-week oral toxicity study of a combination of eight chemicals in rats: Comparison with the toxicity of the individual compounds. Food Chem Toxicol 1990;28:623-631.
11. Yokel RA. Blood-brain barrier flux of aluminum, manganese, iron and other metals suspected to contribute to metal-induced neurodegeneration. J Alzheimers Dis 2006;10:223-253.
12. Zheng W. Neurotoxicology of the brain barrier system: New implications. J Toxcol 2001;9:711-719.
13. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates. New York: Academic Press; 1986.
14. Volonte C, Amadio S, Cavaliere F, D'Ambrosi N, Vacca F, Bernardi G. Extracellular ATP and neurodegeneration. Curr Drug Targets CNS Neurol Disord 2003;2:403-412.
15. Nadler JV. Role of excitatory pathways in the hippocampal damage produced by kainic acid. Adv Biochem Psychopharmacol 1981;27:395-402.
16. Anderson MC, Chung E, Van Woert MH. Strychnine seizure potentiation by azaspirodecanedione anxiolytics in rats. Eur J Pharmacol 1988;155:279-283.
17. Narahashi T, Frey JM, Ginsburg JS, Roy ML. Sodium and GABA-activated channels as the targets of pyrethroids and cyclodienes. Toxical Lett 1992;64/65:429-436.
18. Bouwknecht JA, Spiga F, Staub DR, Hale MW, Shekhar A, Lowry CA. Differential effects of exposure to low-light or highlight open-field on anxiety-related behavior: Relationship to c-Fos expression in serotonergic and non-serotonergic neurons in the dorsal raphe nucleus. Brain Res Bull 2007;72:32-43.
19. Liu Y, Nakamura S. Stress-induced plasticity of monoamine axons. Front Biosci 2006;11:1794-1801.
20. Chaney DS. Monoamine dysfunction and the pathophysiology and treatment of depression. J Clin Psychiatry 1998;59:11-14.
21. Schultz W. Behavioral dopamine signals. Trends Neurosci 2007;30:203-210.
22. Taylor DP, Riblet LA, Stanton HC, Eison AS, Temple DL. Dopamine and antianxiety activity. Pharmacol Biochem Behav 1982;17:25-35.
23. Blows WT. Neurotransmitters of the brain: Serotonin, noradrenaline (norepinephrine), and dopamine. J Neurosci Nurs 2000;32:234-238.
24. Tessitore A, Hariri RA, Fera F, Smith GW, Chase NT, Hyde MT, Weinderger RD, Mattay SV. Dopamine modulates the response of the human amygdala: A study in Parkinson's disease. J Neurosci 2002;22:9099-9103.
25. Prediger RD, Batista LC, Medeiros R, Pandolfo P, Florio JC, Takahashi R. The risk is in the air: Intranasal administration of MPTP to rats reproducing clinical features of Parkinson's disease. Exp Neurol 2006;202:391-403.
26. Carlezon WA, Begin C, DiNieri JA, Baumann MH, Richards MR, Todtenkopf MS, Rothman RB, Ma Z, Lee DY, Cohen BM. Depressive-like effects of the κ-opioid receptor agonist salvinorin A on behavior and neurochemistry in rats. J Pharmacol Exp Ther 2006;316:440-447.
27. Olson EB, Morgan WP. Rat brain monoamine levels related to behavioral assessment. Life Sci 1982;30:2095-2100.
28. Checkley S. Monoamine, depression and antidepressant drugs. Pharmacopsychiatry 1988;21:6-8.